RxDoctor Payments Data

Carolyn Bigelow, MD

Hematology · Jackson, MSNPI 1144259235

Payments from drug & device makers

$171,325in general payments, 2019–2025

Across 688 payments — averaging $249.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$69K
  • Johnson & Johnson$42K
  • Bristol Myers Squibb$19K
  • AstraZeneca$18K
  • Boehringer Ingelheim Canada Ltd.ltee$13K
  • Astellas Pharma US Inc$2K
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$8,0857%
  • Speaking & faculty fees$78,89166%
  • Travel & lodging$19,35816%
  • Food & beverage$12,34910%
  • Education$4320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation70$69,059
Johnson & Johnson(2 entities)93$42,471
Bristol Myers Squibb54$18,893
AstraZeneca(2 entities)35$17,995
Boehringer Ingelheim Canada Ltd.ltee2$13,141
Astellas Pharma US Inc34$1,602
Amgen26$970
Sanofi37$862
Novartis30$650
Merck31$481
Gilead19$372
Genentech USA, Inc.18$328
Takeda Pharmaceuticals U.S.A., Inc.18$320
Seagen Inc.14$284
Pfizer15$270
AbbVie14$250
ADC Therapeutics America, Inc.7$246
Sanofi-aventis U.S. LLC11$243
Bayer9$156
Jazz Pharmaceuticals Inc.4$151
Exelixis Inc.7$142
Rigel Pharmaceuticals, Inc.8$139
Daiichi Sankyo Inc.6$114
Emmaus Medical, Inc.7$112
Sobi, Inc2$96
Beigene USA, Inc.6$92
GSK5$91
Blueprint Medicines Corporation6$89
EMD Serono, Inc.5$81
E.r. Squibb & Sons, L.L.C.6$80
Pharmacyclics LLC, An Abbvie Company4$77
AVEO Pharmaceuticals, Inc.4$73
Adaptive Biotechnologies Corporation4$72
Servier Pharmaceuticals LLC4$64
Eisai Inc.3$62
Regeneron Healthcare Solutions, Inc.3$55
Karyopharm Therapeutics Inc.3$52
Verastem, Inc.4$52
Pharmaessentia USA Corporation2$50
Secura Bio, Inc.4$50
Stemline Therapeutics Inc.2$48
Coherus Oncology, Inc.2$48
Tesaro, Inc.3$47
Novo Nordisk2$46
Ipsen Biopharmaceuticals, Inc3$45
Legend Biotech USA Inc.2$42
Sanofi US Services Inc.2$40
Seqirus USA Inc2$39
Acrotech Biopharma Inc.2$38
Pharmacosmos Therapeutics Inc.2$34
Dova Pharmaceuticals2$32
Global Blood Therapeutics, Inc.2$31
Geron Corporation1$27
Teva Pharmaceuticals USA, Inc.2$26
Agios Pharmaceuticals, Inc.2$26
Acceleron Pharma, Inc.2$25
HEMA Biologics, LLC1$24
Invivyd Inc1$22
Tempus AI, Inc1$21
Morphosys, US Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,672
Medicare patients
237
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide52$784,547
Lenalidomide54$722,851
JakafiRuxolitinib Phosphate36$591,459
PomalystPomalidomide27$494,612
ImbruvicaIbrutinib23$329,119
FabrazymeAgalsidase Beta44$316,614
SprycelDasatinib32$254,435
VenclextaVenetoclax12$48,662
EliquisApixaban57$37,334
Deferasirox40$22,646
OxycontinOxycodone Hcl20$18,060
XareltoRivaroxaban12$17,090
Imatinib Mesylate13$2,062
Acyclovir116$1,232
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$18,893$784,54752 claims
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$80$749,04659 claims
Incyte CorporationJakafi$69,059$591,45936 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$77$329,11923 claims
SanofiFabrazyme$862$316,61444 claims
AbbVieVenclexta$250$48,66212 claims
PfizerEliquis$270$37,33457 claims
Johnson & JohnsonXarelto$42,471$17,09012 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$26$1,232116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other hematology in Jackson

Where these figures come from

Is this you, or does something look wrong? →